You are here:

fondaparinux sodium (Arixtra)

Advice

In the absence of a submission from the holder of the marketing authorisation:

fondaparinux sodium 1.5mg/0.3mL solution for injection, pre-filled syringe (Arixtra ®): is not recommended for use in NHSScotland.                                   

Indication under review: treatment of acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: fondaparinux sodium (Arixtra)
SMC Drug ID: 668/10
Manufacturer: GlaxoSmithKline UK Ltd
Indication: Treatment of acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 13 December 2010

Back